Is Esperion Therapeutics, Inc. (ESPR) a Buy, Sell, or Hold?
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$3.18 USD
$0 (0.0%)
- Volume
- 59.09M
- Average Volume
- 15.45M
- Market Capitalization
- $661.15M
- P/E Ratio
- -131.40
- Dividend Yield
- 99.37%
- Price Target
- $3.16
- Year High
- $4.18
- Year Low
- $1.10
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.53
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Sheldon L. Koenig |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ESPR |
| CUSIP | 29664W105 |
| CIK | 0001434868 |
| Web | https://www.esperion.com |
| Phone | 734 887 3903 |
| Currency | USD |
| Employees | 294 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -1.77 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.53 |
| Quick Ratio | 1.18 |
| Cash Ratio | 0.52 |
Sales & Book Value
| Annual Sales | $403.14M |
| Price / Sales | 1.58 |
| Cash Flow | -0.07 |
| Price / Cash Flow | -36.35 |
| Price / Book | -2.60 |
Price Target and Rating
| Average Stock Price Forecast | $3.16 |
| High Stock Price Forecast | $3.28 |
| Low Stock Price Forecast | $3.16 |
| Forecast Upside/Downside | 0.63% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 25 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.11 |
| Trailing P/E Ratio | -131.40 |
| PEG Ratio | -0.40 |
| P/E Growth | -0.40 |
| Net Income | $-22.68M |
| Net Margin | -1.77% |
| Pretax Margin | -1.33% |
| Return on Equity | 1.99% |
| Return on Assets | -1.60% |
Financials Score
| AltmanZ Score | -2.88 |
| Piotroski Score | 3.00 |
| Working Capital | 159.1M |
| Total Assets | 462.53M |
| Ebit | 39.79M |
| Market Cap | 661.15M |
| Total Liabilities | 770.46M |
Poll Results
About Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stock
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program. Established in 2008, the company's corporate offices are situated in Ann Arbor, Michigan. ...
Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger
2026-07-10 08:02:28
Stockholders of Esperion Therapeutics NASDAQ: ESPR approved the company's merger agreement with Essence Parent and Essence MergerCo at a special meeting held virtually on July 8, 2026, according to remarks delivered during the meeting.
2026-06-17 15:25:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is se.
2026-05-26 08:00:00
– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction in LDL-C in Statin Intolerant Adults – ANN ARBOR, Mich., May 26, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from a Phase 2 study of bempedoic acid in children, along with an additional post hoc analysis from CLEAR Outcomes describing patient traits associated an enhanced LDL-C lowering with bempedoic acid.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2026-05-14 16:30:00
ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
2026-05-14 11:46:08
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
2026-05-13 08:00:00
– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase 2 Study Demonstrated Bempedoic Acid Treatment Reduced LDL-C in Children with Heterozygous Familial Hypercholesterolemia (HeFH) Congruent with Reductions in Adult Exposures – – New Analyses from CLEAR Outcomes Trial Identified Factors Associated With Enhanced LDL-C Reductions in Adult Patients – ANN ARBOR, Mich., May 13, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that two new abstracts and three encore abstracts have been accepted for presentation at the European Atherosclerosis Society (EAS) Congress 2026 taking place on May 24-27, 2026, in Athens, Greece.
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC
2026-05-05 13:15:00
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating
2026-05-04 11:48:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to funds managed by ARCHIMED. Under the terms of the proposed transaction, shareholders of Esperion will receive $3.16 per share in cash and the right to participate in contingent milestone payments for each share of Esperion that they own. KSF is se.
Frequently Asked Questions
-
What is the current Esperion Therapeutics, Inc. (ESPR) stock price?
-
Esperion Therapeutics, Inc.(NASDAQ:ESPR) stock price is $3.18 in the last trading session. During the trading session, ESPR stock reached the peak price of $4.18 while $1.1 was the lowest point it dropped to. The percentage change in ESPR stock occurred in the recent session was 0.0% while the dollar amount for the price change in ESPR stock was $0.
-
ESPR's industry and sector of operation?
-
The NASDAQ listed ESPR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ESPR?
-
Benjamin O. Looker | Corporate Secretary, Chief Legal & Corporate Affairs Officer
Tiffany Aldrich | Associate Director of Corporate Communications
Glenn Brame | Chief Technical Operations Officer
Stephen Pinkosky | Vice President of Drug Discovery of Early Pre-Clinical Development
Betty Jean Swartz | Chief Business Officer -
How many employees does ESPR have?
-
Number of ESPR employees currently stands at 294. ESPR operates from 3891 Ranchero Drive, Ann Arbor, MI 48108, US.
-
Link for ESPR official website?
-
Official Website of ESPR is: https://www.esperion.com
-
How do I contact ESPR?
-
ESPR could be contacted at phone #734 887 3903 and can also be accessed through its website. ESPR operates from 3891 Ranchero Drive, Ann Arbor, MI 48108, US.
-
How many shares of ESPR are traded daily?
-
The average number of ESPR shares traded daily for last 3 months was 15.45M.
-
What is the market cap of ESPR currently?
-
The market value of ESPR currently stands at $661.15M with its latest stock price at $3.18